Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

2.

Subcutaneous Administration of Carbidopa Enhances Oral Levodopa Pharmacokinetics: A Series of Studies Conducted in Pigs, Mice, and Healthy Volunteers.

Shaltiel-Karyo R, Caraco Y, Zawaznik E, Weinstock I, Nemas M, Oren S, Yacoby-Zeevi O, LeWitt PA.

Clin Neuropharmacol. 2019 Jul/Aug;42(4):111-116. doi: 10.1097/WNF.0000000000000345.

PMID:
31192808
3.

Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease.

LeWitt PA, Giladi N, Navon N.

Parkinsonism Relat Disord. 2019 Aug;65:131-138. doi: 10.1016/j.parkreldis.2019.05.032. Epub 2019 May 22.

PMID:
31176632
4.

Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.

LeWitt PA, Lipsman N, Kordower JH.

Mov Disord. 2019 Sep;34(9):1274-1278. doi: 10.1002/mds.27722. Epub 2019 May 28.

PMID:
31136023
5.

Post-traumatic Origin of Unilateral Restless Leg Syndrome.

LeWitt PA.

Mov Disord Clin Pract. 2018 Mar 23;5(3):323-324. doi: 10.1002/mdc3.12594. eCollection 2018 May-Jun. No abstract available.

6.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.

PMID:
30663606
7.

Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale.

Ondo W, Hashem V, LeWitt PA, Pahwa R, Shih L, Tarsy D, Zesiewicz T, Elble R.

Mov Disord Clin Pract. 2017 Nov 23;5(1):60-65. doi: 10.1002/mdc3.12560. eCollection 2018 Jan-Feb.

8.

Delayed Hypersensitivity Reaction to OnabotulinumtoxinA.

LeWitt PA.

Mov Disord Clin Pract. 2018 Mar 9;5(3):321-322. doi: 10.1002/mdc3.12575. eCollection 2018 May-Jun.

9.

Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study.

Mahajan A, Zillgitt A, Alshammaa A, Patel N, Sidiropoulos C, LeWitt PA, Bowyer S.

Brain Sci. 2018 Aug 22;8(9). pii: E159. doi: 10.3390/brainsci8090159.

10.

At last, a randomised controlled trial of apomorphine infusion.

LeWitt PA.

Lancet Neurol. 2018 Sep;17(9):732-733. doi: 10.1016/S1474-4422(18)30284-9. Epub 2018 Jul 25. No abstract available.

PMID:
30055904
11.

Comment on 'Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson's Disease' by Hiller et al.

LeWitt PA.

Mov Disord. 2018 May;33(5):855. doi: 10.1002/mds.27379. Epub 2018 May 3. No abstract available.

PMID:
29722456
12.

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.

LeWitt PA, Verhagen Metman L, Rubens R, Khanna S, Kell S, Gupta S.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):47-55. doi: 10.1097/WNF.0000000000000269.

13.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H.

J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155-161. doi: 10.1089/jamp.2016.1354. Epub 2017 Nov 21.

14.

Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation.

Sidiropoulos C, Bowyer SM, Zillgitt A, LeWitt PA, Bagher-Ebadian H, Davoodi-Bojd E, Schwalb JM, Rammo R, Air E, Soltanian-Zadeh H.

Case Rep Neurol Med. 2017;2017:9653520. doi: 10.1155/2017/9653520. Epub 2017 Jul 4.

15.

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL.

J Neurol Sci. 2017 May 15;376:84-90. doi: 10.1016/j.jns.2017.02.042. Epub 2017 Feb 21.

16.

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2017 Apr 3;9:89. doi: 10.3389/fnagi.2017.00089. eCollection 2017.

17.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

18.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

19.

GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.

Sidiropoulos C, LeWitt PA, Odekerken VJ, Schuurman PR, de Bie RM.

Neurology. 2016 Aug 16;87(7):745-6. doi: 10.1212/WNL.0000000000003027. No abstract available.

PMID:
27527541
20.

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2016 Jul 26;8:178. doi: 10.3389/fnagi.2016.00178. eCollection 2016.

21.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.

Lancet Neurol. 2016 Aug;15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. Review.

PMID:
27478953
22.

Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

Loeffler DA, LeWitt PA, Camp DM.

Mov Disord. 2016 Aug;31(8):1134-8. doi: 10.1002/mds.26711. Epub 2016 Jul 14. Review. No abstract available.

23.

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Hampson NB, Kieburtz KD, LeWitt PA, Leinonen M, Freed MI.

Int J Neurosci. 2017 Mar;127(3):276-284. doi: 10.1080/00207454.2016.1194274. Epub 2016 Jun 27.

PMID:
27345931
24.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.

PMID:
27090868
25.

Levodopa therapy for Parkinson disease: A look backward and forward.

LeWitt PA, Fahn S.

Neurology. 2016 Apr 5;86(14 Suppl 1):S3-12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. Review.

PMID:
27044648
26.

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133.

27.

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Loeffler DA, Smith LM, Coffey MP, Aasly JO, LeWitt PA.

J Neural Transm (Vienna). 2016 Mar;123(3):179-87. doi: 10.1007/s00702-015-1479-0. Epub 2015 Nov 3.

PMID:
26526034
28.

New levodopa therapeutic strategies.

LeWitt PA.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40. doi: 10.1016/j.parkreldis.2015.09.021. Epub 2015 Sep 8. Review.

PMID:
26459662
29.

Quantitative Analysis of Voice in Parkinson Disease Compared to Motor Performance: A Pilot Study.

Silbergleit AK, LeWitt PA, Peterson EL, Gardner GM.

J Parkinsons Dis. 2015;5(3):517-24. doi: 10.3233/JPD-140526.

PMID:
26406131
30.

Successful Management of Hemorrhage-Associated Hemiballism After Subthalamic Nucleus Deep Brain Stimulation with Pallidal Stimulation: a Case Report.

Pabaney A, Ali R, Lewitt PA, Sidiropoulos C, Schwalb JM.

World Neurosurg. 2015 Oct;84(4):1176.e1-3. doi: 10.1016/j.wneu.2015.06.070. Epub 2015 Jul 9.

PMID:
26164193
31.

The pharmacodynamics of placebo: expectation effects of price as a proxy for efficacy.

LeWitt PA, Kim S.

Neurology. 2015 Feb 24;84(8):766-7. doi: 10.1212/WNL.0000000000001294. Epub 2015 Jan 28. No abstract available.

PMID:
25632090
32.

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

LeWitt PA.

Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1. Review.

PMID:
25449210
33.

Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.

Espay AJ, LeWitt PA, Kaufmann H.

Mov Disord. 2014 Dec;29(14):1710-9. doi: 10.1002/mds.26048. Epub 2014 Oct 9. Review.

PMID:
25297066
34.

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Lewitt PA, Mouradian MM.

Neurology. 2014 May 6;82(18):1574-5. doi: 10.1212/WNL.0000000000000390. Epub 2014 Apr 9.

PMID:
24719487
35.

Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease.

Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP.

Parkinsonism Relat Disord. 2014 Jun;20(6):590-5. doi: 10.1016/j.parkreldis.2014.02.022. Epub 2014 Mar 5.

36.

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.

LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC.

Mov Disord. 2014 Jan;29(1):75-82. doi: 10.1002/mds.25742. Epub 2013 Dec 13.

PMID:
24339234
37.

3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.

Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L; Arizona Parkinson's Disease Consortium.

Mov Disord. 2013 Oct;28(12):1653-60. doi: 10.1002/mds.25555. Epub 2013 Jul 19.

PMID:
23873789
38.

Tardive dyskinesia caused by tetrabenazine.

LeWitt PA.

Clin Neuropharmacol. 2013 May-Jun;36(3):92-3. doi: 10.1097/WNF.0b013e318290cd41.

PMID:
23673911
39.

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH; Xeomin US Blepharospasm Study Group.

J Neural Transm (Vienna). 2013 Sep;120(9):1345-53. doi: 10.1007/s00702-013-0998-9. Epub 2013 Feb 23.

40.

Norepinephrine: the next therapeutics frontier for Parkinson's disease.

Lewitt PA.

Transl Neurodegener. 2012 Jan 13;1(1):4. doi: 10.1186/2047-9158-1-4.

41.

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.

LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group.

J Neural Transm (Vienna). 2013 Jul;120(7):1069-81. doi: 10.1007/s00702-012-0925-5. Epub 2012 Dec 4.

42.

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).

Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM.

Neurology. 2012 Jul 10;79(2):163-9. doi: 10.1212/WNL.0b013e31825f0451. Epub 2012 Jun 27.

PMID:
22744665
43.

Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations.

Lewitt PA, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ.

Clin Neuropharmacol. 2012 May-Jun;35(3):103-10. doi: 10.1097/WNF.0b013e31824e4d7d.

PMID:
22406623
44.

Is levodopa toxic? Insights from a brain bank.

LeWitt PA, Dubow J, Singer C.

Neurology. 2011 Oct 11;77(15):1414-5. doi: 10.1212/WNL.0b013e31823435a4. Epub 2011 Sep 14. No abstract available.

PMID:
21917780
45.

Localizing imbalance in progressive supranuclear palsy: is the thalamus the "fall guy"?

Sidiropoulos C, Lewitt PA.

Neurology. 2011 Jul 12;77(2):92-3. doi: 10.1212/WNL.0b013e318223c7b1. Epub 2011 May 25. No abstract available.

PMID:
21613602
46.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

PMID:
21419704
47.

"Sensory trick" in hemichorea-hemiballism and in Parkinson's disease tremor.

Lewitt PA, Gostkowski MT.

Mov Disord. 2010 Jul 15;25(9):1312-3. doi: 10.1002/mds.23104. No abstract available.

PMID:
20629143
48.

Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?

Lewitt PA.

Neurology. 2010 Apr 13;74(15):1169-70. doi: 10.1212/WNL.0b013e3181d90076. Epub 2010 Mar 17. No abstract available.

PMID:
20237309
49.

Mao-B inhibitor know-how: back to the pharm.

Burke WJ.

Neurology. 2009 Dec 8;73(23):2048; author reply 2048. doi: 10.1212/WNL.0b013e3181c7756b. No abstract available.

PMID:
19996086
50.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.

Supplemental Content

Loading ...
Support Center